A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

NCT04451772 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: Elsubrutinib
DRUG: Placebo for Elsubrutinib
DRUG: Upadacitinib
DRUG: Placebo for Upadacitinib

Sponsor

AbbVie